Tauvid (flortaucipir F 18) is the first radioactive tracer that's used in positron emission tomography (PET) scans for people with possible Alzheimer's disease (AD). It helps your provider to identify tangled nerve fibers in the brain, one of the hallmark traits of AD. Tauvid (flortaucipir F 18) is given intravenously (IV) by a healthcare provider before your imaging study.
Tauvid (flortaucipir F 18) is a radioactive tracer used during PET scans for people who are suspected to have Alzheimer's disease (AD). Specifically, this tracer helps your provider see if there are tangled fibers your brain, and if so, where they might be. Tauvid (flortaucipir F 18) works by attaching to a protein called tau. In most people, tau proteins help to maintain the structure of nerve cells in the brain. In people with AD, tau proteins build up and tangle with the other proteins, which causes damage to the nerve cells. Tauvid (flortaucipir F 18) tags these abnormal proteins so your provider can see which nerve cells are affected.
Tauvid (flortaucipir F 18) is typically injected into the veins by a healthcare provider on your imaging day. It's given about an hour and a half before the PET scan.
Most people experience few to no side effects while using Tauvid (flortaucipir F 18) as directed. Those who did report side effects experienced symptoms such as headache, injection site pain, and raised blood pressure. Let your provider know if you experience any of these side effects after the injection.
Similar to many other diagnostic agents, Tauvid (flortaucipir F 18) is radioactive. In general, the more you're exposed to something that's radioactive, the higher your risk for cancer. But please note that your healthcare provider will only use a very small amount of Tauvid (flortaucipir F 18) for imaging. If you're concerned about the safety of Tauvid (flortaucipir F 18) or other diagnostic agents, talk with your provider.
No. There isn't enough information to know if Tauvid (flortaucipir F 18) is safe or works well to help diagnose chronic traumatic encephalopathy, or CTE. Early research suggests it might not attach as well to the tau proteins found in people with CTE. Speak to your provider about other options.